Ribavirin Concentrations, Laboratory Variables, and Clinical Outcomes During Treatment of Hepatitis C Infection with First Generation Direct-Acting Antivirals
European Journal of Clinical and Biomedical Sciences
Volume 5, Issue 3, June 2019, Pages: 51-57
Received: Jul. 12, 2019;
Accepted: Aug. 20, 2019;
Published: Sep. 9, 2019
Views 627 Downloads 76
Halina Michur, Institute of Liver Studies, King’s College Hospital, London, UK
Phillip Morgan, Institute of Liver Studies, King’s College Hospital, London, UK
Ivana Carey, Institute of Liver Studies, King’s College Hospital, London, UK
Nigel Brown, Department of Clinical Chemistry, Wansbeck General Hospital, Ashington, UK
Nigel Heaton, Institute of Liver Studies, King’s College Hospital, London, UK
Michael Heneghan, Institute of Liver Studies, King’s College Hospital, London, UK
Kosh Agarwal, Institute of Liver Studies, King’s College Hospital, London, UK
John Michael Tredger, Institute of Liver Studies, King’s College Hospital, London, UK
In treating hepatitis C infection, identification of reliable markers predicting virological non-response appear central to improving outcome and to prompting changes in dynamic treatment approaches. The interrelationship of ribavirin (RBV) concentrations and laboratory variables with clinical outcomes was evaluated in HCV patients treated with ribavirin, and with or without early direct acting antivirals (DAA). Correlations between RBV concentration, laboratory variables (haemoglobin, absolute lymphocyte, platelet and neutrophil counts, serum creatinine and hepatitis C viral load) and patients’ characteristics associated with sustained virological response (SVR) were investigated using multivariate analysis. The 76 patients studied all received interferon (INF) and RBV, with 37 additionally given Boceprevir or Telaprevir. Significant correlations were noted between week 1 RBV concentration and subsequent total exposure at weeks 2, 4 and 12 (P < 0.0001). RBV concentrations in excess of 1.0 mg/L (week 1) and 2.0 mg/L (week 2) provided targets for avoiding breakthrough (P < 0.05). SVR was greater in patients without cirrhosis (73.3% vs. 41.3%; P < 0.01). All patients with an absolute haemoglobin (Hb) fall >30 g/L (week 8) experienced higher SVR rates (P < 0.03). RBV concentrations above 2.7 mg/L at week 4 or later increased the likelihood of Hb falls >30 g/L. Six factors were predictive of SVR in univariate analysis, and three in multivariate analysis. There is an association between SVR and absolute lymphocyte count, IL-28B CC genotype, and HCV-RNA load fall at week 1 (>80 %) or week 2 (>90 %) in HCV patients treated with INF/RBV and early DAA.
John Michael Tredger,
Ribavirin Concentrations, Laboratory Variables, and Clinical Outcomes During Treatment of Hepatitis C Infection with First Generation Direct-Acting Antivirals, European Journal of Clinical and Biomedical Sciences.
Vol. 5, No. 3,
2019, pp. 51-57.
Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, et al. Ribavirin revisited in the era of direct- acting antiviral therapy for hepatitis C virus infection. Liver Int. 2017; 37 (1): 5-18.
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann Intern Med. 2017; 166 (9): 637-48.
Karasawa T, Saito T, Ueno Y, et al. Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis. Int J Med Sci. 2013; 10 (11): 1575-7.
Morello J, Rodríguez-Novoa S, Jiménez-Nácher I, et al. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008; 62 (6): 1174-80.
Kovari H, Russmann S, Ledergerber B, et al. Ribavirin concentrations do not predict sustained virological response in HIV/HCV- coinfected patients treated with ribavirin and pegylated interferon in the Swiss HIV cohort study. PLoS One. 2015; 10 (7): e0133879.
Mondelli MU. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? Hepatology. 2014; 60 (4): 1126-9.
Werner JM, Serti E, Chepa-Lotrea X, et al. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology. 2014; 60 (4): 1160-9.
Brown NW, Morgan PE, Agarwal K, et al. Concentration monitoring of plasma ribavirin: Validation of a liquid chromatography-mass spectrometric method and clinical sample collection. Ther Drug Monit. 2016; 38 (1): 50-8.
Lindahl K, Stahle L, Bruchfeld A, et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology. 2005; 41 (2): 275-9.
Kuntzen T, Kuhn S, Kuntzen D, et al. Influence of ribavirin serum levels on outcome of antiviral treatment and anemia in hepatitis C virus infection. PLoS One. 2016; 11 (7): e0158512.
Abenavoli L, Mazza M, Almasio PL. The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepat Mon. 2011; 11 (4): 240-6.
Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother. 2010; 54 (4): 1647-9.
Pradat P, Virlogeux V, Gagnieu MC, et al. Ribavirin at the era of novel direct antiviral agents for the treatment of hepatitis C virus infection: Relevance of pharmacological monitoring. Hepat Mon. 2015; 15 (9): 1-5.
Pugh R, Murray-Lyon I, Dawson J. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
Nakayama M, Kobayashi H, Fukushima K, et al. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int. 2016; 10 (1): 158-68.
Bodeau S, Durand-Maugard C, Lemaire-Hurtel AS, et al. The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse. Ther Drug Monit. 2013; 35 (6): 791-5.
Conti F, Vukotic R, Lorenzini S, et al. Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. Ann Hepatol. 2014; 13 (2): 196-203.
Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007; 5 (1): 124-9.
Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005; 43 (3): 425-33.
Janczewska E, Flisiak R, Zarebska-Michaluk D, et al. Effect of peginterferon or ribavirin dosing on efficacy of therapy with telaprevir in treatment-experienced patients with chronic hepatitis C and advanced liver fibrosis: A multicentre cohort study. Medicine (Baltimore). 2015; 94 (38): e1411.
Slavenburg S, Huntjens-Fleuren HW, Dofferhoff TS, et al. Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit. 2011; 33 (1): 40-4.
Oswald G, Alzoubi K, Abed M, et al. Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol. 2014; 114 (4): 311-7.
Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut. 2005; 54 (7): 1014-20.
Harrington PR, Fleischer R, Connelly SM, et al. Ribavirin reduces absolute lymphocyte counts in hepatitis C virus-infected patients treated with interferon-free, direct-acting antiviral regimens. Clin Infect Dis. 2015; 61 (6): 974-7.
Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trials. Hepatology. 2013; 57 (3): 974-84.
Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anaemia is associated with higher sustained virologicresponse rate. Gastroenterology. 2010; 139 (5): 1602-11, 11. e1.
Sievert W, Dore GJ, McCaughan GW, et al. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology. 2011; 53 (4): 1109-17.
Thompson AJ. Genetic factors and hepatitis C virus infection. Gastroenterology. 2012; 142 (6): 1335-9.
Tamai H, Shimizu R, Shingaki N, et al. Prediction of sustained virological response to telaprevir-based triple therapy using viral response within 2 Weeks. Hepat Res Treat. 2014; 2014: 748935.
Thompson A, Devine S, Kattan M, et al. Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. PLoS One. 2014; 9 (8): e103370.
Poordad F, Landaverde C. Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype patients. Therap Adv Gastroenterol. 2009; 2 (2): 91-7.
Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015; 60 (12): 1743-51.